New preprint showcases results in an ALS mouse model
Miramoon Pharma's pipeline targets many disorders and we are very happy to report the results of a research study in which one
INVESTORS & COLLABORATORS
MP-004, our lead candidate for Retinitis Pigmentosa, is granted Orphan Drug Designation by the FDA
At Miramoon Pharma, we are delighted to announce that MP-004, our lead product in development for the treatment of retinitis pigmentosa, has
“Retos” project awarded
At Miramoon Pharma, we are delighted to announce the award of a Public-Private Collaboration Project (MICIN-AEI) valued at over 900,000 euros. This
New publications page
We have added a Publications page on our website to share our published research. And we have included a preprint section too!
Gobierno Vasco
Hazitek - I+D "MIRANEBT"
- 1
- 2